Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders (Q28280510)

Expert Review of Anticancer Therapy

Europe PubMed Central

title

Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders (English)

0 references

1 reference

Francesco Turturro

1

0 references

language of work or name

English

0 references

publication date

January 2007

0 references

published in

0 references

volume

7

0 references

issue

1

0 references

page(s)

11-7

0 references

cites work

Clinical use of rituximab in haematological malignancies

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.1.11

Monoclonal antibody therapy of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.1.11

From the bench to the bedside: ways to improve rituximab efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.1.11

Radioimmunotherapy of non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.1.11

Clinical experience with denileukin diftitox (ONTAK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.1.11

Denileukin diftitox: a concise clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.1.11

Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.1.11

Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.1.11

A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.1.11

Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.1.11

Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.1.11

Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.1.11

Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.1.11

Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.1.11